Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 9.14% is in line with its 5-year average of 8.52%, around the middle of its 5-year range (4.45%–11.54%).
41.05% above its 12-month average of 6.48%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.48%.
RETURN ON ASSETS (ROA)
9.14%
RETURN ON ASSETS (ROA) AVG TTM
6.48%
RETURN ON ASSETS (ROA) AVG 3Y
7.48%
RETURN ON ASSETS (ROA) AVG 5Y
8.52%
RETURN ON ASSETS (ROA) AVG 10Y
9.00%
RETURN ON ASSETS (ROA) AVG 15Y
9.19%
RETURN ON ASSETS (ROA) AVG 20Y
9.23%
CURRENT VS TTM AVG
+41.05%
CURRENT VS 3Y AVG
+22.15%
CURRENT VS 5Y AVG
+7.32%
CURRENT VS 10Y AVG
+1.57%
CURRENT VS 15Y AVG
-0.54%
CURRENT VS 20Y AVG
-0.99%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+77.82%
vs the sector median at left
Amgen Inc.
Market Cap
$203.12B
Return on Assets (ROA)
9.14%
TTM Avg
6.48%
3Y Avg
7.48%
5Y Avg
8.52%
Market Cap
$185.26B
Return on Assets (ROA)
19.90%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$183.36B
Return on Assets (ROA)
-6.56%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$177.12B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
Market Cap
$240.97B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$156.51B
Return on Assets (ROA)
2.16%
TTM Avg
3.75%
3Y Avg
6.08%
5Y Avg
7.08%
Market Cap
$252.62B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$146.59B
Return on Assets (ROA)
4.33%
TTM Avg
4.68%
3Y Avg
5.89%
5Y Avg
6.01%
Market Cap
$135.05B
Return on Assets (ROA)
15.04%
TTM Avg
13.09%
3Y Avg
12.00%
5Y Avg
11.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | $203.12B | 9.14% | 6.48% | 7.48% | 8.52% |
| Novo Nordisk A/S (NVO)vs › | $185.26B | 19.90% | 20.27% | 22.54% | 48.60% |
| Gilead Sciences, Inc. (GILD)vs › | $183.36B | -6.56% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT)vs › | $177.12B | 4.97% | 11.99% | 10.28% | 9.45% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $240.97B | 6.17% | 6.31% | 6.46% | 7.20% |
| Pfizer Inc. (PFE)vs › | $156.51B | 2.16% | 3.75% | 6.08% | 7.08% |
| AstraZeneca PLC (AZN)vs › | $252.62B | 9.03% | 7.88% | 6.26% | 4.99% |
| Danaher Corporation (DHR)vs › | $146.59B | 4.33% | 4.68% | 5.89% | 6.01% |
| Intuitive Surgical, Inc. (ISRG)vs › | $135.05B | 15.04% | 13.09% | 12.00% | 11.68% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.27B | 16.06% | 6.37% | 11.74% | 14.58% |
ROA
9.1%
ROE
74.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 8.51% |
| 2024-12-31 | 4.45% |
| 2023-12-31 | 6.91% |
| 2022-12-31 | 10.06% |
| 2021-12-31 | 9.63% |
| 2020-12-31 | 11.54% |
| 2019-12-31 | 13.13% |
| 2018-12-31 | 12.64% |
| 2017-12-31 | 2.48% |
| 2016-12-31 | 9.95% |
| 2015-12-31 | 9.69% |
| 2014-12-31 | 7.47% |
| 2013-12-31 | 7.68% |
| 2012-12-31 | 8.00% |
| 2011-12-31 | 7.54% |
| 2010-12-31 | 10.64% |
| 2009-12-31 | 11.62% |
| 2008-12-31 | 11.51% |
| 2007-12-31 | 9.14% |
| 2006-12-31 | 8.73% |
| 2005-12-31 | 12.54% |
| 2004-12-31 | 8.09% |
| 2003-12-31 | 8.63% |
| 2002-12-31 | -5.69% |
| 2001-12-31 | 17.38% |
| 2000-12-31 | 21.08% |
| 1999-12-31 | 26.89% |
| 1998-12-31 | 23.51% |
| 1997-12-31 | 20.72% |
| 1996-12-31 | 24.58% |
